Suvaxyn Circo

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
06-11-2018
Produktens egenskaper Produktens egenskaper (SPC)
06-11-2018

Aktiva substanser:

porcine circovirus vaccine (inactivated, recombinant)

Tillgänglig från:

Zoetis Belgium SA

ATC-kod:

QI09AA07

INN (International namn):

porcine circovirus vaccine (inactivated, recombinant)

Terapeutisk grupp:

Pigs (for fattening)

Terapiområde:

Immunologicals for suidae, Inactivated viral vaccines

Terapeutiska indikationer:

For active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (PCV2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with PCV2.,

Produktsammanfattning:

Revision: 2

Bemyndigande status:

Authorised

Tillstånd datum:

2018-02-07

Bipacksedel

                                15
B. PACKAGE LEAFLET
16
PACKAGE LEAFLET:
SUVAXYN CIRCO EMULSION FOR INJECTION FOR PIGS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE,
IF DIFFERENT
Marketing authorization holder and manufacturer responsible for batch
release:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Suvaxyn Circo emulsion for injection for pigs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
One dose (2 ml) contains:
ACTIVE SUBSTANCES:
Inactivated recombinant chimeric porcine circovirus type 1containing
the porcine
circovirus type 2 ORF2 protein
2.3 – 12.4 RP*
ADJUVANT:
Squalane
Poloxamer 401
Polysorbate 80
8 µl (0.4% v/v)
4 µl (0.2% v/v)
0.64 µl (0.032%
v/v)
EXCIPIENTS:
Thiomersal
0.2 mg
*
Relative potency unit determined by ELISA antigen quantification (
_in vitro _
potency test) compared to a
reference vaccine.
White homogenous emulsion.
4.
INDICATION(S)
For active immunisation of pigs from 3 weeks of age against Porcine
Circovirus type 2 (PCV2) to
reduce viral load in blood and lymphoid tissues and fecal shedding
caused by infection with PCV2.
Onset of immunity: from 3 weeks after vaccination.
Duration of immunity: 23weeks after vaccination
5.
CONTRAINDICATIONS
None.
17
6.
ADVERSE REACTIONS
A transient increase in body temperature (on average 1 °C) is very
common during the first 24 hours after
vaccination. In individual pigs the temperature increase compared to
pre-treatment may commonly exceed
2 °C. This resolves spontaneously within 48 hours without treatment.
Immediate mild hypersensitivity-like
reactions may occur uncommonly after vaccination, resulting in
transient clinical signs such as vomiting,
diarrhea or depression. These clinical signs normally resolve without
treatment. Anaphylaxis may occur in
very rare cases. In case of such reactions, appropriate treatment is
recommended.
Local tissue reactions in the form of swelling at the injection site,
which m
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Suvaxyn Circo emulsion for injection for pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (2 ml) contains:
ACTIVE SUBSTANCE:
Inactivated recombinant chimeric porcine circovirus type 1 containing
the
porcine circovirus type 2 ORF2 protein
_ _
2.3 – 12.4 RP*
ADJUVANT:
Squalane
Poloxamer 401
Polysorbate 80
EXCIPIENTS:
8 µl (0.4% v/v)
4 µl (0.2% v/v)
0.64 µl (0.032%
v/v)
Thiomersal
0.2 mg
*
Relative potency unit determined by ELISA antigen quantification (
_in vitro _
potency test) compared to a
reference vaccine.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Emulsion for injection.
White homogenous emulsion.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs (for fattening)
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of pigs from 3 weeks of age against porcine
circovirus type 2 (PCV2) to reduce viral
load in blood and lymphoid tissues and fecal shedding caused by
infection with PCV2.
Onset of immunity: from 3 weeks after vaccination.
Duration of immunity: 23 weeks after vaccination
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
3
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
None
Special precautions to be taken by the person administering the
veterinary medicinal product to animals
Not applicable.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
A transient increase in body temperature (on average 1°C) is very
common during the first 24 hours after
vaccination. In individual pigs the temperature increase compared to
pre-treatment may commonly exceed
2 °C. This resolves spontaneously within 48 hours without treatment.
Immediate mild hypersensitivity-like reactions may occur uncommonly
after vaccination, resulting in
transient clinical signs such as vomiting, diarrhea or depression.
These clinical signs normally resolve without
treatment. Anaphylaxis may occur in very rar
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 06-11-2018
Produktens egenskaper Produktens egenskaper bulgariska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 20-04-2018
Bipacksedel Bipacksedel spanska 06-11-2018
Produktens egenskaper Produktens egenskaper spanska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 20-04-2018
Bipacksedel Bipacksedel tjeckiska 06-11-2018
Produktens egenskaper Produktens egenskaper tjeckiska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 20-04-2018
Bipacksedel Bipacksedel danska 06-11-2018
Produktens egenskaper Produktens egenskaper danska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 20-04-2018
Bipacksedel Bipacksedel tyska 06-11-2018
Produktens egenskaper Produktens egenskaper tyska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 20-04-2018
Bipacksedel Bipacksedel estniska 06-11-2018
Produktens egenskaper Produktens egenskaper estniska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 20-04-2018
Bipacksedel Bipacksedel grekiska 06-11-2018
Produktens egenskaper Produktens egenskaper grekiska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 20-04-2018
Bipacksedel Bipacksedel franska 06-11-2018
Produktens egenskaper Produktens egenskaper franska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 20-04-2018
Bipacksedel Bipacksedel italienska 06-11-2018
Produktens egenskaper Produktens egenskaper italienska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 20-04-2018
Bipacksedel Bipacksedel lettiska 06-11-2018
Produktens egenskaper Produktens egenskaper lettiska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 20-04-2018
Bipacksedel Bipacksedel litauiska 06-11-2018
Produktens egenskaper Produktens egenskaper litauiska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 20-04-2018
Bipacksedel Bipacksedel ungerska 06-11-2018
Produktens egenskaper Produktens egenskaper ungerska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 20-04-2018
Bipacksedel Bipacksedel maltesiska 06-11-2018
Produktens egenskaper Produktens egenskaper maltesiska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 20-04-2018
Bipacksedel Bipacksedel nederländska 06-11-2018
Produktens egenskaper Produktens egenskaper nederländska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 20-04-2018
Bipacksedel Bipacksedel polska 06-11-2018
Produktens egenskaper Produktens egenskaper polska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 20-04-2018
Bipacksedel Bipacksedel portugisiska 06-11-2018
Produktens egenskaper Produktens egenskaper portugisiska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 20-04-2018
Bipacksedel Bipacksedel rumänska 06-11-2018
Produktens egenskaper Produktens egenskaper rumänska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 20-04-2018
Bipacksedel Bipacksedel slovakiska 06-11-2018
Produktens egenskaper Produktens egenskaper slovakiska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 20-04-2018
Bipacksedel Bipacksedel slovenska 06-11-2018
Produktens egenskaper Produktens egenskaper slovenska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 20-04-2018
Bipacksedel Bipacksedel finska 06-11-2018
Produktens egenskaper Produktens egenskaper finska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 20-04-2018
Bipacksedel Bipacksedel svenska 06-11-2018
Produktens egenskaper Produktens egenskaper svenska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 20-04-2018
Bipacksedel Bipacksedel norska 06-11-2018
Produktens egenskaper Produktens egenskaper norska 06-11-2018
Bipacksedel Bipacksedel isländska 06-11-2018
Produktens egenskaper Produktens egenskaper isländska 06-11-2018
Bipacksedel Bipacksedel kroatiska 06-11-2018
Produktens egenskaper Produktens egenskaper kroatiska 06-11-2018
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 20-04-2018

Sök varningar relaterade till denna produkt

Visa dokumenthistorik